Abstract

Elevated plasma TGs increase risk of cardiovascular disease in women. Estrogen treatment raises plasma TGs in women, but molecular mechanisms remain poorly understood. Here we explore the role of cholesteryl ester transfer protein (CETP) in the regulation of TG metabolism in female mice, which naturally lack CETP. In transgenic CETP females, acute estrogen treatment raised plasma TGs 50%, increased TG production, and increased expression of genes involved in VLDL synthesis, but not in nontransgenic littermate females. In CETP females, estrogen enhanced expression of small heterodimer partner (SHP), a nuclear receptor regulating VLDL production. Deletion of liver SHP prevented increases in TG production and expression of genes involved in VLDL synthesis in CETP mice with estrogen treatment. We also examined whether CETP expression had effects on TG metabolism independent of estrogen treatment. CETP increased liver β-oxidation and reduced liver TG content by 60%. Liver estrogen receptor α (ERα) was required for CETP expression to enhance β-oxidation and reduce liver TG content. Thus, CETP alters at least two networks governing TG metabolism, one involving SHP to increase VLDL-TG production in response to estrogen, and another involving ERα to enhance β-oxidation and lower liver TG content. These findings demonstrate a novel role for CETP in estrogen-mediated increases in TG production and a broader role for CETP in TG metabolism.

Highlights

  • Elevated plasma TGs increase risk of cardiovascular disease in women

  • We demonstrate that the effects of cholesteryl ester transfer protein (CETP) expression require small heterodimer partner (SHP) or estrogen receptor (ER ), two nuclear receptors governing liver TG metabolism

  • VLDL apoB levels were significantly higher in estrogen-treated CETP mice relative to WT mice, suggesting a higher number of VLDL particles after estrogen treatment in CETP mice (Fig. 1I)

Read more

Summary

MATERIALS and METHODS

An expanded methods section is available in the online data supplement. CETP transgenic mice were purchased from Jackson Laboratories [C57BL/6-Tg(CETP)UCTP20Pnu/J, Stock No: 001929]. CETP mice were bred with ER flox/flox mice with Cre recombinase under control of the albumin promoter [liver-specific knockout of ER (LKO-ER ), ER flox/flox;ALB-Cre+/ , described previously [17]] to generate LKO-ER CETP (ER flox/flox;ALB-Cre+/ ;CETP+/ ) and LKO-ER littermates. CETP mice were bred with SHPflox/flox mice with Cre recombinase under control of the albumin promoter [LKO-SHP, SHPflox/flox;ALB-Cre+/ , described previously [18]] to generate LKO-SHP CETP (SHPflox/flox;ALB-Cre+/ ;CETP+/ ) and LKO-SHP littermates. Mice were euthanized 24 h after estrogen treatment to prevent changes associated with long-term estrogen replacement, such as reduced adiposity, reduced insulin, and increased free fatty acids [19].

Lipid and lipoprotein analysis
Estrogen raises plasma TGs in CETP females but not WT females
Estrogen treatment raises TG production in CETP females
CETP requires liver SHP to increase TG production with estrogen treatment
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call